Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 5/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 2/20 | 0.46 |
| ▸ | REN | P00797 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918356 | 0.90 | CTSL (0.49) | CTSLCTSBADORA3ADORA2AADORA2B | |
| SCHEMBL27428946 | 0.90 | CTSL (0.49) | CTSLCTSBADORA3ADORA2AADORA2B | |
| SCHEMBL27428889 | 0.90 | CTSL (0.48) | CTSLCTSBADORA3ADORA2AADORA2B | |
| SCHEMBL27428796 | 0.88 | MME (0.54) | CTSLADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL30918338 | 0.88 | CTSL (0.55) | CTSLCTSBMMEECE1CTSS | |
| SCHEMBL30918343 | 0.87 | BACE1 (0.46) | CTSLCTSBREN | |
| SCHEMBL5972669 | 0.82 | MME (0.55) | CTSLCTSBMMEECE1CTSS | |
| SCHEMBL4958111 | 0.82 | MME (0.55) | CTSLCTSBMMEECE1CTSS | |
| SCHEMBL4576533 | 0.80 | CTSB (0.59) | CTSLCTSBCTSSCTSK | |
| SCHEMBL30958909 | 0.80 | BACE1 (0.39) | CTSLCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243217-A1 | CRYSTAL FORMS OF PEPTIDE MOLECULES | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | WO | disclosed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | CTSL 743/4885CTSB 1288/4885ADORA3 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.